Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 266

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer

Open access
Vuk‐Pavlović, Stanimir, Bulur, Peggy A., Lin, Yi, Qin, Rui, Szumlanski, Carol L., Zhao, Xinghua, Dietz, Allan B.·2010·The Prostate

Abstract

OBJECTIVE: To determine if the levels of circulating myeloid‐derived suppressor cells increase with progression of prostate cancer (PCa); to determine if such cells could contribute to the relative inefficiency of PCa immunotherapy. MATERIALS AND METHODS: We analyzed peripheral blood mononuclear cells isolated from untreated PCa patients (uPCa; N = 18; mean age ± SD: 72.1 ± 6.9 years), tPCa (N = 22; 72.8 ± 9.8 years) and age matched controls (AMC; N = 12; 68.8 ± 7.5 years). We quantified surface marker phenotype, differentiation potential, effects on T cell proliferation and intracellular cytokines. RESULTS: We observed an unexpectedly high percentage of a type of myeloid‐derived suppressor cells, CD14+HLA‐DR low/− monocytes, in tPCa (30.7 ± 15.0% of CD14+ cells) relative to AMC (4.1 ± 6.5%, P < 0.0001) and uPCa (10.6 ± 14.3%, P = 0.0001). The levels of CD14+ HLA‐DR low/− cells were significantly correlated with circulating PSA levels and treatment with LHRH‐agonist leuprolide in combination with either an antiandrogen or dexamethasone. Monocytes from tPCa inhibited autologous T cell proliferation statistically significantly more effectively than AMC monocytes and were defective in their ability to differentiate into phenotypically mature dendritic cells. Isolated CD14+HLA‐DR low/− cells expressed higher levels of intracellular interleukin‐10 and suppressed T cell proliferation more effectively than isolated CD14+HLA‐DR+ cells. CONCLUSIONS: This is the first report of CD14+ cells exhibiting reduced expression of HLA‐DR molecules in PCa patients. These cells suppress immune cell function in vitro and, plausibly, in vivo, a finding that must be factored into the design of immunotherapy protocols for PCa patients. Prostate 70: 443–455, 2010. © 2009 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/pros.21078

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 43 references

Cited by

See all 266

Metadata

Authors
Vuk‐Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X., & Dietz, A. B.
Venue
The Prostate
Publisher
Wiley
Published
2009-11-09
Volume
70
Issue
4
Pages
443-455
ISSN
  • 0270-4137 (ISSN-L)
  • 1097-0045
OpenAlex
W2031200699
Cited by
266
References
43
FWCI
8.66
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer. https://app.cochat.ai/papers/10.1002/pros.21078
The paper
Vuk‐Pavlović, S., Bulur, P. A., Lin, Y., Qin, R., Szumlanski, C. L., Zhao, X., & Dietz, A. B. (2010). Immunosuppressive CD14+HLA‐DRlow/− monocytes in prostate cancer. The Prostate. https://doi.org/10.1002/pros.21078

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.